The ICM and Clevexel Pharma, pharmaceutical company headed by Christian Bloy, have just signed a partnership agreement to develop new terminating molecules against diseases of the central nervous system and more specifically Parkinson’s disease. This alliance will allow the development of new treatments to fight neurological diseases.
CleveXel Pharma, pharmaceutical company specialised in the development of drugs against Parkinson’s disease and other neurodegenerative diseases, has signed by the end of 2015, a strategic partnership with the ICM. This partnership aims to develop terminating molecules against these neurodegenerative diseases, create new adapted treatments against movement disorders and improve the quality of life of patients with these severe and disabling pathologies.
The company develops a portfolio of product candidates to treat Parkinson’s disease, including CVXL-0107 molecule. A phase IIa clinical trial has just began within the Clinical Investigation Centre at the ICM, to assess the efficiency of this molecule against motor fluctuations and involuntary movements (dyskinesia) induced by the standard treatment for Parkinson’s disease, L-Dopa.